Menu

FDA Report on BPA’s Health Effects Raises Concerns

The pre-peer review assessment finds the compound has “minimal effects,” but endocrinologists and others say key data have yet to come out.

Feb 28, 2018
Ashley Yeager

WIKIMEDIA, HTEINK.MINBisphenol A, as it is used now in consumer products, is safe, the US Food and Drug Administration (FDA) announced last week (February 23) in a statement. The conclusion is based on a pre-peer review draft report describing experiments showing “minimal effects” on rats exposed to different doses of the compound, commonly called BPA. But the announcement has drawn criticism.

“It was disappointing to me to read that [statement],” Gail Prins, a researcher at the University of Illinois at Chicago, tells Newsweek. “I’m not saying what they did was bad work. [The results] are valid, but they are not complete.”

The study, conducted by the FDA’s National Center for Toxicological Research (NCTR), is one part of CLARITY-BPA, the Consortium Linking Academic and Regulatory Insights on BPA Toxicity. The other component includes ongoing studies at academic institutions using offspring of rats derived from the core study. Together, the experiments aim to investigate the full range of health effects BPA could have on humans. Prins is running one of the institution-based experiments, looking for a connection between the compound and prostate cancer.

“It is premature to draw conclusions based on the release of one component of a two-part report,” Laura Vandenberg, a spokesperson for the Endocrine Society, says in a statement. The NCTR draft report “included the results of one government study with a partial data set and has yet to undergo peer review,” she notes.

In the FDA’s study, NCTR researchers investigated how BPA affected rats’ growth, weight, and tumor development, but it did not explore how the compound affects brain development.    

See “BPA Disrupts Zebrafish Neurogenesis

“The endpoints studied here do not encompass the full effects of endocrine-disrupting chemicals, especially because the whole point of this study was to compare the NCTR’s endpoints with more sensitive effects evaluated by endocrinologists,” Vandenberg says in the statement. “Furthermore, the NCTR’s data does not provide assurance of BPA’s safety. They found certain BPA doses are linked to a higher rate of mammary gland tumors, which is concerning.”

In the FDA statement, Stephen Ostroff, deputy commissioner for foods and veterinary medicine, says that the significance of the increase incidence of tumors would be evaluated through the peer review process.

But as NPR notes, the point might be moot. Plastic- and can-makers have already moved away from using BPA in their products.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.